Solid Biosciences Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Solid Biosciences amended its Certificate of Incorporation four times between October 2022 and June 2026, progressively increasing authorized Common Stock from 300M shares (post-reverse split) to 480M shares. The October 2022 amendment implemented a 1-for-15 reverse stock split and reduced authorized shares to 60M Common; subsequent amendments in June 2024, June 2025, and June 2026 expanded authorized Common to 120M, 240M, and 480M respectively. Preferred Stock remained at 10M authorized throughout. No counterparties, cash, or operational details disclosed.
Why this rating
Routine capital structure amendments. Authorizations do not reflect issuances and are standard shareholder governance actions for biotech companies managing dilution flexibility. Immaterial relative to $317.7M market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.